Nosca-Méréprine (Noscapine Hydrochloride Monohydrate)

Nosca-Méréprine is an antitussive that acts on the central cough centre to reduce cough frequency.

• Cough: provides symptomatic relief of dry, non‑productive cough.
• Acute bronchitis: helps decrease cough intensity during the early phase of the illness.
• Upper respiratory tract infection: reduces cough associated with viral upper airway inflammation.

• Noscapine Hydrochloride Monohydrate suppresses cough by modulating the medullary cough centre, likely through sigma‑1 receptor interaction, which reduces the neuronal excitability that triggers the cough reflex. It acts peripherally without opioid activity, offering a non‑opioid antitussive effect.

Adverse reactions may occur with any antitussive medication. Most are mild and reversible.

Common Side Effects

• Nausea: mild stomach upset reported in some patients.
• Dizziness: transient light‑headedness, especially after initial doses.
• Drowsiness: occasional sleepiness, advise caution with driving.
• Headache: mild to moderate headache may develop.
• Gastrointestinal discomfort: abdominal cramps or loose stools.
• Mild rash: skin redness or itching.

Serious or Rare Side Effects

• Allergic reaction: hives, swelling, or difficulty breathing.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Hepatic dysfunction: elevated liver enzymes or jaundice.
• Hematologic abnormalities: rare blood dyscrasias such as neutropenia.
• Seizures: very rare central nervous system events.
• Respiratory depression: unlikely but reported in overdose situations.

Use of Nosca-Méréprine should be guided by clinical judgment and patient history.

• Pediatric use: limit to children over 2 years unless prescribed otherwise.
• Hepatic impairment: consider dose adjustment or close monitoring.
• Concomitant CNS depressants: avoid or use with caution due to additive drowsiness.
• Allergy history: screen for previous hypersensitivity to noscapine or related compounds.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Nosca-Méréprine may interact with other medicines that affect the central nervous system or drug metabolism.

Major Interactions (Avoid)

• Other antitussives: combined use can increase risk of excessive sedation.
• Monoamine oxidase inhibitors (MAOIs): may potentiate central effects.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise noscapine plasma levels.
• CNS depressants (e.g., benzodiazepines, antihistamines): monitor for enhanced drowsiness.
• Anticoagulants: observe for any change in bleeding tendency.
• Antihypertensives: watch for additive hypotensive effects.